DEA Faces Internal Conflict Over Proposed Marijuana Rescheduling

The Justice Department is defending a proposal to move cannabis to Schedule III of the Controlled Substances Act, a move that would alter the DEA’s traditional role. Historically, DEA agents have targeted marijuana traffickers, seized large quantities, and testified about its health risks. In recent hearings, a DEA scientist highlighted the drug’s abuse potential, widespread diversion, and the absence of standardized products or solid medical evidence.

Critics argue that the shift reflects political and commercial influences rather than scientific criteria established by Congress. They warn that lowering restrictions could increase availability, reduce perceived risk, and lead to higher rates of addiction, impaired driving, and psychiatric issues. The debate underscores a tension between the agency’s law-enforcement mandate and emerging policy pressures.